Marker Therapeutics: Next Major Leap in T-Cell Based Immunotherapies for Cancer



Marker Therapeutics (NASDAQ: MRKR), Inc. is a a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based …

1 Comment

  1. Company has great potential, their therapy is potentially groundbreaking and extremely cost effective compared to CART therapy.

Leave a Reply

Your email address will not be published.


*